Yanbing Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanbing Han has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
An‐Chen Guo
Department of Neurology Beijing Tiantan Hospital Capital Medical University Beijing China
1 shared publicationChangqing Liu
Department of Neurology Chongqing Sanbo Jiangling Hospital Chongqing China
1 shared publicationChonglun Guo
Epilepsy Center Suichuan County People's Hospital Ji'an Jiangxi China
1 shared publication- Fanfan Shi
Department of Clinical Research and Management, Center of Biostatistics, Design, Measurement and Evaluation (CBDME) West China Hospital, Sichuan University Chengdu Sichuan China
1 shared publication Fang Chen
Department of Neurology Sichuan Provincial People's Hospital Jinniu Hospital Chengdu Sichuan China
1 shared publicationHaizhi Guo
Department of Neurology Ziyang First People's Hospital Ziyang Sichuan China
1 shared publication
Latest Publications
- Open Access
- 18 October 2026
- Published by Wiley in Advanced Science
- p. e78329
Astrocyte‐Associated ABCA1/APOE Responses Accompany Hippocampal Lipid Remodeling and Ectopic Neuronal Accumulation During Epileptogenesis
Temporal lobe epilepsy (TLE) is characterized by progressive hippocampal remodeling, including reactive astrogliosis and aberrant neuronal positioning. Although lipid disturbances are implicated in epileptogenesis, how astrocyte‐associated lipid responses relate to hippocampal remodeling remains poorly understood. Here, human TLE and kainic acid (KA)‐treated mouse transcriptomic datasets identified ATP‐binding cassette transporter A1 (ABCA1)/Abca1 as a nominal astrocyte‐associated candidate, while KA‐ and pilocarpine‐induced status epilepticus (SE) elicited astrocyte‐associated ABCA1/apolipoprotein E (APOE) responses. Ectopic granule cells and immature neurons accumulated in the hilus and were spatially associated with ABCA1‐positive cells, including astrocytic profiles; perilipin 2 (PLIN2)‐positive puncta were nearby. Pretreatment with the retinoid X receptor (RXR) agonist bexarotene increased hippocampal ABCA1 expression, delayed severe KA‐induced behavioral seizure onset, and was associated with fewer chronic spontaneous seizures and reduced ectopic neuronal accumulation. Post‐SE bexarotene administration was associated with lower seizure frequency, ectopic neuronal accumulation, and astrocytic marker‐positive cell densities. Multi‐omic profiling identified bexarotene‐associated metabolic and lipidomic changes; transmission electron microscopy (TEM) showed a smaller mean hilar neuronal lipid‐droplet area per image, and protein analyses identified early changes in p38 and extracellular signal‐regulated kinase 1/2 (Erk1/2) phosphorylation. Together, these findings warrant further investigation of astrocyte‐associated lipid pathways as potential therapeutic targets in epilepsy‐associated hippocampal remodeling.
- 18 October 2026
- Published by Wiley in Advanced Science
- p. e78329
Open AccessAstrocyte‐Associated ABCA1/APOE Responses Accompany Hippocampal Lipid Remodeling and Ectopic Neuronal Accumulation During Epileptogenesis
Temporal lobe epilepsy (TLE) is characterized by progressive hippocampal remodeling, including reactive astrogliosis and aberrant neuronal positioning. Although lipid disturbances are implicated in epileptogenesis, how astrocyte‐associated lipid responses relate to hippocampal remodeling remains poorly understood. Here, human TLE and kainic acid (KA)‐treated mouse transcriptomic datasets identified ATP‐binding cassette transporter A1 (ABCA1)/Abca1 as a nominal astrocyte‐associated candidate, while KA‐ and pilocarpine‐induced status epilepticus (SE) elicited astrocyte‐associated ABCA1/apolipoprotein E (APOE) responses. Ectopic granule cells and immature neurons accumulated in the hilus and were spatially associated with ABCA1‐positive cells, including astrocytic profiles; perilipin 2 (PLIN2)‐positive puncta were nearby. Pretreatment with the retinoid X receptor (RXR) agonist bexarotene increased hippocampal ABCA1 expression, delayed severe KA‐induced behavioral seizure onset, and was associated with fewer chronic spontaneous seizures and reduced ectopic neuronal accumulation. Post‐SE bexarotene administration was associated with lower seizure frequency, ectopic neuronal accumulation, and astrocytic marker‐positive cell densities. Multi‐omic profiling identified bexarotene‐associated metabolic and lipidomic changes; transmission electron microscopy (TEM) showed a smaller mean hilar neuronal lipid‐droplet area per image, and protein analyses identified early changes in p38 and extracellular signal‐regulated kinase 1/2 (Erk1/2) phosphorylation. Together, these findings warrant further investigation of astrocyte‐associated lipid pathways as potential therapeutic targets in epilepsy‐associated hippocampal remodeling.
Folic acid supplementation and prevention of adverse offspring outcomes among women with epilepsy: An observational study
Objective: Folic acid (FA) is essential for fetal development, while the benefits and optimal dose in pregnant women with epilepsy (PWWE) remain unclear. This study explores effects of FA supplementation, dose, and initiation time on offspring outcomes in PWWE. Methods: This multi‐center cohort recruited PWWE from 58 hospitals in China. Anti‐seizure medication (ASM) and FA exposures were categorized by first‐trimester use. The primary outcome was a composite of preterm birth, low birth weight (LBW), major congenital anomalies (MCAs), fetal death, and neurodevelopmental delay. Logistic regression models assessed the associations between FA exposure, dose, initiation time, and adverse outcomes, adjusting for demographics and epilepsy characteristics, with stratification by maternal ASM use. Dose–response relationships were analyzed using restricted cubic splines. Results: Among 1013 women with 1209 pregnancies, 952 received FA. In ASM‐exposed pregnancies, FA supplementation was associated with lower risks of composite adverse offspring outcomes (adjusted odds ratio [aOR] .59, 95% confidence interval [CI] .387–.911) and fetal death (aOR .127, 95% CI .054–.296), whereas no significant differences were observed between preconception and first‐trimester initiation. Compared to no supplement, supplementation with .4 mg/day protected against fetal death (aOR .185, 95% CI .078–.428); doses exceeding .4 mg/day further reduced risk of composite adverse outcomes (aOR .343, 95% CI .162–.675), and doses above 1 mg additionally showed trends toward decreased preterm birth in ASM‐exposed pregnancies (aOR .338, 95% CI .104–.943). Compared with .4 mg supplementation, doses above 1 mg/day were associated with a lower risk of LBW (aOR .208, 95% CI .05–.58). Significance: FA supplementation was associated with lower risks of composite adverse offspring outcomes in ASM‐exposed pregnancies, specifically at doses exceeding .4 mg. No such associations were observed in pregnancies not exposed to ASMs. However, the optimal upper limit of high‐dose FA supplementation requires further investigation.
Folic acid supplementation and prevention of adverse offspring outcomes among women with epilepsy: An observational study
Objective: Folic acid (FA) is essential for fetal development, while the benefits and optimal dose in pregnant women with epilepsy (PWWE) remain unclear. This study explores effects of FA supplementation, dose, and initiation time on offspring outcomes in PWWE. Methods: This multi‐center cohort recruited PWWE from 58 hospitals in China. Anti‐seizure medication (ASM) and FA exposures were categorized by first‐trimester use. The primary outcome was a composite of preterm birth, low birth weight (LBW), major congenital anomalies (MCAs), fetal death, and neurodevelopmental delay. Logistic regression models assessed the associations between FA exposure, dose, initiation time, and adverse outcomes, adjusting for demographics and epilepsy characteristics, with stratification by maternal ASM use. Dose–response relationships were analyzed using restricted cubic splines. Results: Among 1013 women with 1209 pregnancies, 952 received FA. In ASM‐exposed pregnancies, FA supplementation was associated with lower risks of composite adverse offspring outcomes (adjusted odds ratio [aOR] .59, 95% confidence interval [CI] .387–.911) and fetal death (aOR .127, 95% CI .054–.296), whereas no significant differences were observed between preconception and first‐trimester initiation. Compared to no supplement, supplementation with .4 mg/day protected against fetal death (aOR .185, 95% CI .078–.428); doses exceeding .4 mg/day further reduced risk of composite adverse outcomes (aOR .343, 95% CI .162–.675), and doses above 1 mg additionally showed trends toward decreased preterm birth in ASM‐exposed pregnancies (aOR .338, 95% CI .104–.943). Compared with .4 mg supplementation, doses above 1 mg/day were associated with a lower risk of LBW (aOR .208, 95% CI .05–.58). Significance: FA supplementation was associated with lower risks of composite adverse offspring outcomes in ASM‐exposed pregnancies, specifically at doses exceeding .4 mg. No such associations were observed in pregnancies not exposed to ASMs. However, the optimal upper limit of high‐dose FA supplementation requires further investigation.